...
首页> 外文期刊>Heart failure reviews >Biomarkers in cancer therapy related cardiac dysfunction (CTRCD)
【24h】

Biomarkers in cancer therapy related cardiac dysfunction (CTRCD)

机译:癌症治疗相关心脏功能障碍的生物标志物(CTRCD)

获取原文
获取原文并翻译 | 示例

摘要

Biomarkers are at the cornerstone of preventive measures and contribute to the screening process. More recently, biomarkers have been used to gauge the biological response to the employed therapies. Since it is ubiquitously used to detect subclinical disease process, biomarkers also have found its place in cancer therapy related cardiac dysfunction (CTRCD). The aim of this review is to comprehensively present up-to-date knowledge of biomarkers in CTRCD and highlight some of the future biomedical technologies that may strengthen the screening process, and/or provide new insight in pathological mechanisms behind CTRCD.
机译:生物标志物是预防措施的基石,有助于筛查过程。最近,生物标志物被用来衡量对所用疗法的生物反应。由于广泛用于检测亚临床疾病过程,生物标记物也在癌症治疗相关心功能不全(CTRCD)中找到了位置。本综述的目的是全面介绍CTRCD中生物标记物的最新知识,并强调未来可能加强筛查过程的一些生物医学技术,和/或提供CTRCD背后病理机制的新见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号